AD Outcomes Improved With Lebrikizumab and Topical Steroids

The ADhere study compared responses at 16 weeks to the investigational biologic and topical corticosteroids vs topical corticosteroids alone in adults and adolescents with moderate to severe AD.
Medscape Medical News

source https://www.medscape.com/viewarticle/986934?src=rss